Effects  ||| S:0 E:8 ||| NNS
of  ||| S:8 E:11 ||| IN
bore  ||| S:11 E:16 ||| JJ
diameter  ||| S:16 E:25 ||| NN
of  ||| S:25 E:28 ||| IN
porous  ||| S:28 E:35 ||| JJ
hydroxyapatite  ||| S:35 E:50 ||| JJ
scaffolds  ||| S:50 E:60 ||| NN
on  ||| S:60 E:63 ||| IN
three-dimensional  ||| S:63 E:81 ||| JJ
dynamic  ||| S:81 E:89 ||| JJ
cultivation  ||| S:89 E:101 ||| NN
of  ||| S:101 E:104 ||| IN
osteoblasts  ||| S:104 E:116 ||| VBG
To  ||| S:116 E:119 ||| TO
explore  ||| S:119 E:127 ||| VB
the  ||| S:127 E:131 ||| DT
relationship  ||| S:131 E:144 ||| NN
between  ||| S:144 E:152 ||| IN
bore  ||| S:152 E:157 ||| JJ
diameter  ||| S:157 E:166 ||| NN
of  ||| S:166 E:169 ||| IN
porous  ||| S:169 E:176 ||| JJ
hydroxyapatite  ||| S:176 E:191 ||| NNS
( ||| S:191 E:192 ||| -LRB-
HA ||| S:192 E:194 ||| NNP
)  ||| S:194 E:196 ||| -RRB-
scaffolds  ||| S:196 E:206 ||| NN
and  ||| S:206 E:210 ||| CC
the  ||| S:210 E:214 ||| DT
adhesion ||| S:214 E:222 ||| NN
,  ||| S:222 E:224 ||| ,
proliferation  ||| S:224 E:238 ||| NN
and  ||| S:238 E:242 ||| CC
metabolism  ||| S:242 E:253 ||| NN
of  ||| S:253 E:256 ||| IN
osteoblasts  ||| S:256 E:268 ||| NN
by  ||| S:268 E:271 ||| IN
3D  ||| S:271 E:274 ||| CD
cultivation ||| S:274 E:285 ||| NN
.  ||| S:285 E:287 ||| .
MC3T3-E1  ||| S:287 E:296 ||| NNP
cell  ||| S:296 E:301 ||| NN
suspension  ||| S:301 E:312 ||| NN
was  ||| S:312 E:316 ||| VBD
separately  ||| S:316 E:327 ||| RB
dropped  ||| S:327 E:335 ||| VBD
axially  ||| S:335 E:343 ||| VBN
through  ||| S:343 E:351 ||| IN
different  ||| S:351 E:361 ||| JJ
bore  ||| S:361 E:366 ||| FW
diameter  ||| S:366 E:375 ||| FW
scaffolds  ||| S:375 E:385 ||| FW
( ||| S:385 E:386 ||| -LRB-
Group  ||| S:386 E:392 ||| NNP
A ||| S:392 E:393 ||| NNP
: ||| S:393 E:394 ||| :
150  ||| S:394 E:398 ||| CD
µm ||| S:398 E:400 ||| NN
,  ||| S:400 E:402 ||| ,
Group  ||| S:402 E:408 ||| NNP
B ||| S:408 E:409 ||| NNP
: ||| S:409 E:410 ||| :
300  ||| S:410 E:414 ||| CD
µm ||| S:414 E:416 ||| CD
)  ||| S:416 E:418 ||| -RRB-
to  ||| S:418 E:421 ||| TO
confirm  ||| S:421 E:429 ||| VB
initial  ||| S:429 E:437 ||| JJ
seeding ||| S:437 E:444 ||| NN
.  ||| S:444 E:446 ||| .
Then  ||| S:446 E:451 ||| RB
scaffolds  ||| S:451 E:461 ||| RB
were  ||| S:461 E:466 ||| VBD
transferred  ||| S:466 E:478 ||| VBN
into  ||| S:478 E:483 ||| IN
a  ||| S:483 E:485 ||| DT
perfusion  ||| S:485 E:495 ||| JJ
bioreactor  ||| S:495 E:506 ||| NN
of  ||| S:506 E:509 ||| IN
5 ||| S:509 E:510 ||| CD
%  ||| S:510 E:512 ||| NN
CO2  ||| S:512 E:516 ||| NN
at  ||| S:516 E:519 ||| IN
37°C  ||| S:519 E:524 ||| CD
for  ||| S:524 E:528 ||| IN
5  ||| S:528 E:530 ||| CD
days  ||| S:530 E:535 ||| NNS
with  ||| S:535 E:540 ||| IN
an  ||| S:540 E:543 ||| DT
average  ||| S:543 E:551 ||| JJ
flow  ||| S:551 E:556 ||| NN
of  ||| S:556 E:559 ||| IN
3.4  ||| S:559 E:563 ||| CD
ml ||| S:563 E:565 ||| CD
/ ||| S:565 E:566 ||| CD
min ||| S:566 E:569 ||| NNS
.  ||| S:569 E:571 ||| .
After  ||| S:571 E:577 ||| IN
perfusion  ||| S:577 E:587 ||| JJ
cultivation ||| S:587 E:598 ||| NN
,  ||| S:598 E:600 ||| ,
cell  ||| S:600 E:605 ||| NN
proliferation  ||| S:605 E:619 ||| NN
between  ||| S:619 E:627 ||| IN
different  ||| S:627 E:637 ||| JJ
groups  ||| S:637 E:644 ||| NNS
of  ||| S:644 E:647 ||| IN
scaffolds  ||| S:647 E:657 ||| NN
was  ||| S:657 E:661 ||| VBD
determined  ||| S:661 E:672 ||| VBN
by  ||| S:672 E:675 ||| IN
methyl  ||| S:675 E:682 ||| FW
thiazolyl  ||| S:682 E:692 ||| FW
tetrazolium  ||| S:692 E:704 ||| FW
( ||| S:704 E:705 ||| -LRB-
MTT ||| S:705 E:708 ||| NNP
)  ||| S:708 E:710 ||| -RRB-
assay  ||| S:710 E:716 ||| NN
and  ||| S:716 E:720 ||| CC
cell  ||| S:720 E:725 ||| NN
metabolic  ||| S:725 E:735 ||| NN
activities  ||| S:735 E:746 ||| NNS
were  ||| S:746 E:751 ||| VBD
determined  ||| S:751 E:762 ||| VBN
by  ||| S:762 E:765 ||| IN
glucose  ||| S:765 E:773 ||| JJ
consumption ||| S:773 E:784 ||| NN
.  ||| S:784 E:786 ||| .
Lastly  ||| S:786 E:793 ||| JJ
cell  ||| S:793 E:798 ||| NN
adhesion  ||| S:798 E:807 ||| NNS
and  ||| S:807 E:811 ||| CC
proliferation  ||| S:811 E:825 ||| NN
were  ||| S:825 E:830 ||| VBD
observed  ||| S:830 E:839 ||| VBN
directly  ||| S:839 E:848 ||| RB
by  ||| S:848 E:851 ||| IN
scanning  ||| S:851 E:860 ||| VBG
electronic  ||| S:860 E:871 ||| JJ
microscope  ||| S:871 E:882 ||| NN
( ||| S:882 E:883 ||| -LRB-
SEM ||| S:883 E:886 ||| NNP
) ||| S:886 E:887 ||| -RRB-
.  ||| S:887 E:889 ||| .
The  ||| S:889 E:893 ||| DT
results  ||| S:893 E:901 ||| NNS
of  ||| S:901 E:904 ||| IN
MTT  ||| S:904 E:908 ||| NNP
assay  ||| S:908 E:914 ||| NN
showed  ||| S:914 E:921 ||| VBD
that  ||| S:921 E:926 ||| IN
the  ||| S:926 E:930 ||| DT
optical  ||| S:930 E:938 ||| JJ
density ||| S:938 E:945 ||| NN
/ ||| S:945 E:946 ||| CD
mass  ||| S:946 E:951 ||| NN
ratios  ||| S:951 E:958 ||| NNS
were  ||| S:958 E:963 ||| VBD
1.31  ||| S:963 E:968 ||| CD
±  ||| S:968 E:970 ||| CD
0.26  ||| S:970 E:975 ||| CD
in  ||| S:975 E:978 ||| IN
group  ||| S:978 E:984 ||| NN
A  ||| S:984 E:986 ||| NN
and  ||| S:986 E:990 ||| CC
1.51  ||| S:990 E:995 ||| CD
±  ||| S:995 E:997 ||| CD
0.43  ||| S:997 E:1002 ||| CD
in  ||| S:1002 E:1005 ||| IN
group  ||| S:1005 E:1011 ||| NN
B.  ||| S:1011 E:1014 ||| NNP
There  ||| S:1014 E:1020 ||| EX
was  ||| S:1020 E:1024 ||| VBD
no  ||| S:1024 E:1027 ||| DT
significant  ||| S:1027 E:1039 ||| JJ
difference  ||| S:1039 E:1050 ||| NN
( ||| S:1050 E:1051 ||| -LRB-
t  ||| S:1051 E:1053 ||| JJ
test ||| S:1053 E:1057 ||| NN
,  ||| S:1057 E:1059 ||| ,
P  ||| S:1059 E:1061 ||| NN
=  ||| S:1061 E:1063 ||| SYM
0.36 ||| S:1063 E:1067 ||| CD
) ||| S:1067 E:1068 ||| -RRB-
.  ||| S:1068 E:1070 ||| .
Glucose  ||| S:1070 E:1078 ||| JJ
consumption  ||| S:1078 E:1090 ||| NN
in  ||| S:1090 E:1093 ||| IN
group  ||| S:1093 E:1099 ||| NN
A  ||| S:1099 E:1101 ||| NN
was  ||| S:1101 E:1105 ||| VBD
significantly  ||| S:1105 E:1119 ||| RB
lower  ||| S:1119 E:1125 ||| JJR
than  ||| S:1125 E:1130 ||| IN
that  ||| S:1130 E:1135 ||| DT
in  ||| S:1135 E:1138 ||| IN
group  ||| S:1138 E:1144 ||| NN
B  ||| S:1144 E:1146 ||| NNP
[ ||| S:1146 E:1147 ||| -LRB-
( ||| S:1147 E:1148 ||| -LRB-
162.38  ||| S:1148 E:1155 ||| CD
±  ||| S:1155 E:1157 ||| CD
33.09 ||| S:1157 E:1162 ||| CD
)  ||| S:1162 E:1164 ||| -RRB-
vs  ||| S:1164 E:1167 ||| NNS
( ||| S:1167 E:1168 ||| -LRB-
217.97  ||| S:1168 E:1175 ||| CD
±  ||| S:1175 E:1177 ||| CD
27.91 ||| S:1177 E:1182 ||| CD
)  ||| S:1182 E:1184 ||| -RRB-
µmol ||| S:1184 E:1188 ||| FW
/ ||| S:1188 E:1189 ||| FW
L ||| S:1189 E:1190 ||| NNP
,  ||| S:1190 E:1192 ||| ,
P  ||| S:1192 E:1194 ||| NN
=  ||| S:1194 E:1196 ||| SYM
0.01 ||| S:1196 E:1200 ||| CD
] ||| S:1200 E:1201 ||| -RRB-
.  ||| S:1201 E:1203 ||| .
The  ||| S:1203 E:1207 ||| DT
adhesion ||| S:1207 E:1215 ||| NN
,  ||| S:1215 E:1217 ||| ,
proliferation ||| S:1217 E:1230 ||| NN
,  ||| S:1230 E:1232 ||| ,
pseudopodia  ||| S:1232 E:1244 ||| NN
and  ||| S:1244 E:1248 ||| CC
extracellular  ||| S:1248 E:1262 ||| JJ
matrix  ||| S:1262 E:1269 ||| NN
of  ||| S:1269 E:1272 ||| IN
osteoblasts  ||| S:1272 E:1284 ||| NN
in  ||| S:1284 E:1287 ||| IN
internal  ||| S:1287 E:1296 ||| JJ
part  ||| S:1296 E:1301 ||| NN
of  ||| S:1301 E:1304 ||| IN
scaffolds  ||| S:1304 E:1314 ||| NN
after  ||| S:1314 E:1320 ||| IN
perfusion  ||| S:1320 E:1330 ||| JJ
cultivation  ||| S:1330 E:1342 ||| NN
were  ||| S:1342 E:1347 ||| VBD
observed  ||| S:1347 E:1356 ||| VBN
by  ||| S:1356 E:1359 ||| IN
SEM ||| S:1359 E:1362 ||| NNP
.  ||| S:1362 E:1364 ||| .
With  ||| S:1364 E:1369 ||| IN
excellent  ||| S:1369 E:1379 ||| JJ
biocompatibility ||| S:1379 E:1395 ||| NN
,  ||| S:1395 E:1397 ||| ,
porous  ||| S:1397 E:1404 ||| JJ
HA  ||| S:1404 E:1407 ||| NN
scaffolds  ||| S:1407 E:1417 ||| NNS
are  ||| S:1417 E:1421 ||| VBP
available  ||| S:1421 E:1431 ||| JJ
for  ||| S:1431 E:1435 ||| IN
fabricating  ||| S:1435 E:1447 ||| JJ
tissue  ||| S:1447 E:1454 ||| NN
engineering  ||| S:1454 E:1466 ||| NN
bones ||| S:1466 E:1471 ||| NNS
.  ||| S:1471 E:1473 ||| .
There  ||| S:1473 E:1479 ||| EX
is  ||| S:1479 E:1482 ||| VBZ
no  ||| S:1482 E:1485 ||| DT
effect  ||| S:1485 E:1492 ||| NN
of  ||| S:1492 E:1495 ||| IN
bore  ||| S:1495 E:1500 ||| JJ
diameter  ||| S:1500 E:1509 ||| NN
on  ||| S:1509 E:1512 ||| IN
the  ||| S:1512 E:1516 ||| DT
proliferation  ||| S:1516 E:1530 ||| NN
of  ||| S:1530 E:1533 ||| IN
osteoblasts ||| S:1533 E:1544 ||| NN
.  ||| S:1544 E:1546 ||| .
But  ||| S:1546 E:1550 ||| CC
it  ||| S:1550 E:1553 ||| PRP
affects  ||| S:1553 E:1561 ||| VBZ
the  ||| S:1561 E:1565 ||| DT
metabolic  ||| S:1565 E:1575 ||| JJ
activity  ||| S:1575 E:1584 ||| NN
of  ||| S:1584 E:1587 ||| IN
osteoblasts ||| S:1587 E:1598 ||| NN
.  ||| S:1598 E:1600 ||| .
So  ||| S:1600 E:1603 ||| RB
bore  ||| S:1603 E:1608 ||| JJ
diameter  ||| S:1608 E:1617 ||| NN
may  ||| S:1617 E:1621 ||| MD
be  ||| S:1621 E:1624 ||| VB
increased  ||| S:1624 E:1634 ||| VBN
within  ||| S:1634 E:1641 ||| IN
a  ||| S:1641 E:1643 ||| DT
feasible  ||| S:1643 E:1652 ||| JJ
range  ||| S:1652 E:1658 ||| NN
on  ||| S:1658 E:1661 ||| IN
the  ||| S:1661 E:1665 ||| DT
premise  ||| S:1665 E:1673 ||| NN
of  ||| S:1673 E:1676 ||| IN
mechanical  ||| S:1676 E:1687 ||| JJ
properties ||| S:1687 E:1697 ||| NNS
.  ||| S:1697 E:1699 ||| .
